SCHEMBL154208

SCHEMBL154208

NNc1ccc(Br)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
LMNA P02545 7/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
ALOX12 P18054 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 1/20 0.46
DGAT1 O75907 1/20 0.44
CA12 O43570 1/20 0.43
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1584021 0.98 CA1 (0.48) CA1CA2CA9LMNANPC1
Bromide SCHEMBL20984343 0.98 CA1 (0.48) CA1CA2CA9LMNANPC1
Hydrochloric Acid SCHEMBL29788704 0.98 CA1 (0.48) CA1CA2CA9LMNANPC1
Oxalic Acid SCHEMBL20984246 0.89 LMNA (0.54) CA1CA2CA9LMNANPC1
Phosphoric Acid SCHEMBL20984405 0.89 NPC1 (0.46) CA1CA2CA9LMNANPC1
Sulfuric Acid SCHEMBL20984763 0.89 CA1 (0.54) CA1CA2CA9LMNANPC1
Nitric Acid SCHEMBL20984844 0.86 CA1 (0.47) CA1CA2CA9LMNANPC1
SCHEMBL4668847 0.82 DGAT1 (0.39) CA1CA2CA9LMNANPC1
Hydrochloric Acid SCHEMBL3642581 0.80 DGAT1 (0.38) CA1CA2CA9LMNANPC1
SCHEMBL19267221 0.79 LMNA (0.51) CA1CA2CA9LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114364668-B CDK4/6 inhibitors, and salts and intermediates thereof 甘李药业股份有限公司 2024-07-16 CN claimed
US-20220315532-A1 METHODS FOR PREPARING CDK4/6 INHIBITOR AND SALT AND INTERMEDIATE THEREOF GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2022-10-06 US claimed
EP-3988545-A1 METHODS FOR PREPARING CDK4/6 INHIBITOR AND SALT AND INTERMEDIATE THEREOF Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2022-04-27 EP claimed
CN-114364668-A CDK4/6 inhibitors, salts and intermediates thereof 甘李药业股份有限公司 2022-04-15 CN claimed
WO-2020253865-A1 METHODS FOR PREPARING CDK4/6 INHIBITOR AND SALT AND INTERMEDIATE THEREOF 甘李药业股份有限公司 2020-12-24 WO claimed
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed
WO-2024173646-A1 CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-08-22 WO disclosed
CN-114364668-B CDK4/6 inhibitors, and salts and intermediates thereof 甘李药业股份有限公司 2024-07-16 CN disclosed
US-11787801-B2 Protein kinase inhibitors, preparation method and medical use thereof GAN & LEE PHARMACEUTICALS (CN) 2023-10-17 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-5041155-A Preemergence herbicide mixture for controlling grass; for use with soybeans, corn or sugar cane FMC CORPORATION (US) 1991-08-20 US disclosed
US-4818275-A PREEMERGENCE FMC CORPORATION (US) 1989-04-04 US disclosed
EP-0294375-A1 HERBICIDAL ARYL TRIAZOLINONES. FMC CORP (US) 1988-12-14 EP disclosed
EP-0294375-A4 HERBICIDAL ARYL TRIAZOLINONES. FMC CORP (US) 1988-10-20 EP disclosed
WO-1987003782-A1 HERBICIDAL ARYL TRIAZOLINONES FMC CORPORATION (US) 1987-07-02 WO disclosed
US-4448961-A Substituted anilino pyrimidines ZOECON CORPORATION (US) 1984-05-15 US disclosed
US-4411839-A α-Cyano-β-(trisubstituted phenylhydrazino)-n-ethoxycarbonylacrylamides ZOECON CORPORATION (US) 1983-10-25 US disclosed
US-4042373-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315532-A1 METHODS FOR PREPARING CDK4/6 INHIBITOR AND SALT AND INTERMEDIATE THEREOF CDK4, CDK6, CDK8 CA1 3604/4885CA2 2565/4885CA9 2056/4885
US-11787801-B2 Protein kinase inhibitors, preparation method and medical use thereof ROR1, DMPK, CDK9 CA1 2185/4885CA2 2152/4885CA9 795/4885
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 CA1 1343/4885CA2 3915/4885CA9 3092/4885
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM CA1 4352/4885CA2 4248/4885CA9 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.